Recent

% | $
Quotes you view appear here for quick access.

Affymax, Inc. (AFFY) Message Board

jagan1961 19948 posts  |  Last Activity: 4 hours ago Member since: Oct 31, 1999
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Given the price manipulation, not anyone holding a controlling stakes, no Poison Pills, a great potential break through Drug along with a proven delivery platform makes ARWR an acquisition target.

    When could it happen? The lowest price makes it a very sweet deal for someone, even @25-30$ a share, makes the acquirer genius.

    Definitely someone will scoop this puppy, if the PPS stays this low, even though I wish this go solo, on its own.

    GLTA LONGS

    Sentiment: Strong Buy

  • The delay to report 3 mg/4 mg single dosage, its long lasting action and the previously reported 1 / 2mg action along with today's Dirk's Blog news makes me wonder whether FC is achieved for significantly large number of patients? That is a huge news indeed.

    GLTA LONGS!

    Sentiment: Strong Buy

  • Reply to

    That Gap at $7.94 is just begging to get filled!

    by end2war Apr 23, 2015 1:38 PM
    jagan1961 jagan1961 Apr 23, 2015 1:49 PM Flag

    I don't believe any of the chartist's theory with regard to ARWR price moves. It all depends how many shares are lent by the Institutions to shorties and general availability of Short shares.

    The stock will move past 20-25 range in a jiffy, it all depends on what sort of news we are going to receive from 3/4 mg PH 2 A. If they achieve longer and higher KD effect, coupled with the other drug combos to reach a FC after ARC-520 administration to the patients then you are looking at a terrific run.

    Shorts could do nothing once the news of FC is out as a solo or a combo drug.

    GLTA LONGS!

    Sentiment: Strong Buy

  • jagan1961 jagan1961 Apr 23, 2015 11:25 AM Flag

    I own Jan 2016 options, so I don't need to worry about short term fluctuations. If the ARC 520 and ARC-AAT works as expected you have a 100$ stock by next year.

    GLTA LONGS!

    Sentiment: Strong Buy

  • Reply to

    What Can We Expect to See from ARWR This Week?

    by ginajangelic Apr 22, 2015 1:37 AM
    jagan1961 jagan1961 Apr 23, 2015 12:53 AM Flag

    I don't expect anything happening for 1-2 weeks, unless there is a buyout of some sort. Shorts are in 100% control and the institutions are lending them a big hand as of now.

    I'm staying put for another 8 months till Jan 2016, by which time we will know ARC 520/ARWR is a real stuff or Anzilo is a snake oil salesman! I think he can't be a snake oil salesman, since the scientific team is too big (I heard it is in excess of 50 folks) to keep this scam going for this long, if there is one.

    GLTA LONGS!

    Sentiment: Strong Buy

  • That is the reason despite all the negativity being perpetrated by Shorties and their crony analysts, I'm very optimistic on the final outcome here. If he can't pull it off, Anzilo would have already put up a sale sign when the stock was trading $20 range.

    The shorties will move the stock one day without turning back and will go long big. Most of the individual shareholders would have sold out or chasing the stock at a much higher price.

    The wait should be over by end June/July by which time we should have news on the 3mg/4 mg Ph2 A results.

    GLTA LONGS!

    Sentiment: Strong Buy

  • That fool wants the proof, if this is proven to be working for Complete KD effect then we are looking at $50+ easy, becomes just the only drug in its class.

    Wish I had more dough to increase my share count here.

    GLTA LONGS!

    Sentiment: Strong Buy

  • jagan1961 jagan1961 Apr 22, 2015 11:57 AM Flag

    Those who sold @9+ and @8+ has an incentive to cover to lock in their profit. Almost 20+ mln shares traded after ARWR hit high of $9.50+

    A 40% profit in a week for shorties is a huge money. My goal is still wait it out till Jan 2016.

    GLTA LONGS!

    Sentiment: Strong Buy

  • Shorts are making a tons of money at this juncture and they put tremendous pressure further and further to the downside price.

    They want proof, that is their mantra. They don't believe and trying into not to believe in any of its achievements. Successful conclusion of PH 2 trials of 3 mg /4 mg and ARC-AAT initiation and purchase of NVS assets along with a huge cash balance.

    It is very crucial for Anzilo and team to provide a real update of 3mg/4 mg single dosage trial results as soon as practical. I'm not looking for a complete KD here, it should atleast be an incremental KD proportionate to the dosage. The stock will climb on its own merits despite the Shorties involvement here.

    What is needed is more and more of patience and perseverance. If you believe in this story and if you have additional dough, the price looks extremely attractive and way way oversold.

    GLTA LONGS!

    Sentiment: Strong Buy

  • Someone is deliberately keeping the price low with the help of these Crooks. Everytime a positive news breaks out it is being deliberately sidelined and shorting begins with a vengeance.

    Definitely yesterday many individual shareholders might have burnt big time and it is scary too. For seasoned ones it is fine, the buyout looms very large right now.

    The company don't need any money right now and they have 150 MLN on hand, which will last atleast for 18 months, by which time they will have couple of products in the market place.

    ARC-520 can be manufactured at a commercial scale right now. Having said that $25-30 buyout is not ruled out right now.

    GLTA LONGS!

    Sentiment: Strong Buy

  • Did he go to China and found out 3 mg/4 mg data is bad? Leaked out, then why $9, it should be $4 then.

    If you believe in these analysts then you are doomed.

    GLTA LONGS!

    Sentiment: Strong Buy

  • What a #$%$ the Jeffereies are? Whom they are supporting here?
    The WS is full of croooks and we small investors are just pans with these #$%$s games.

    Jefferies downgraded Arrowhead Research (NASDAQ: ARWR) from Buy to Hold with a price target of $9.00 (from $30.00), in assumed coverage.
    Analyst Eun Yang commented, "HBV market is large; roughly ~2x size of HCV market on WW # pts. While potential for HBV functional cure with lead product ARC-520 exists, on lower-than-expected early efficacy data, we await to see multi-dosing data for potential deeper responses (vs. single-dose). ARWR is to begin multi-dosing Ph2b in ~May 2015 (at 1mg/kg, 1x monthly for 3 months, n=12)."
    The firm raised FY 2015 EPS from ($1.45) to ($1.42) and cut FY 2016 EPS from ($0.43) to ($1.43).
    For an analyst ratings summary and ratings history on Arrowhead Research click here. For more ratings news on Arrowhead Research click here.
    Shares of Arrowhead Research closed at $8.00 yesterday.

    Sentiment: Strong Buy

  • jagan1961 jagan1961 Apr 14, 2015 7:41 AM Flag

    Shorts are all over ARWR, who is lending them this many shares is anybody's guess. Most of the shorted shares are not even reported.

    Hope Anzilo releases 3mg/4 mg data soon, without which the shares will move sideways.

    GLTA LONGS!

    Sentiment: Strong Buy

  • Even though 70%+ shares owned by the institutions and most of the brokerages don't allow to be traded in Margin, I'm puzzled with the way shorts piling on this one. Yesterday's 9 MLN share volume was mostly on the Sell side and with just 18 MLN shares float, how can they churn this much of volume is anybody's guess.

    It is going to be very difficult task for the longs. I used to own a company like Cyclacel, where Ramboti's used to pop up (cancer cure with a pill) and there are folks who used to post great things about the company, ultimately the stock is trading in pennies.

    ARWR needs to release 3mg/4mg data to the market to see, what sort of KD is being achieved, without which this is going to be very tough to determine the movement of this stock. It might even be Risk free to buy after the release of 3mg/4 mg data.

    If the 3mg/4mg data is good and achieves incremental KD, then the stock will move past 2 digits otherwise the stock might fall back below previous lows under $4.

    The way in which the Shorts are piling on this one, I suspect even if there are good results you can scoop the shares much cheaper than its worth even after their 3mg / 4mg positive results, since shorts will not allow the shares to move up until they cover all their shares.

    I'm currently neutral on this one, neither adding to my position nor selling anything.

    GLTA LONGS!

    Sentiment: Strong Buy

  • I suspect this seems to be the case. Look at those who bought today at high 8's and 9's. Unnecessarily the small shareholders lost a ton.

    Looks to me the Anzilo is hand in glove with the institutions to create a false uptick and then kill the individual shareholders.

    GLTA LONGS!

    Sentiment: Strong Buy

  • Reply to

    Today's news is underwhelming....

    by carrix_fool Apr 13, 2015 2:21 PM
    jagan1961 jagan1961 Apr 13, 2015 2:30 PM Flag

    Each dose of ARC-520 has effective till 45 days and upto 2 months. 30 days is very good, even ARWR would not have asked anything of shorter duration.

    GLTA LONGS!

    Sentiment: Strong Buy

  • Looks like some other institutions accumulated more shares today. Watch for the filing.

    GLTA LONGS!

    Sentiment: Strong Buy

  • Reply to

    Such small PPS action

    by tltrooper Apr 13, 2015 11:50 AM
    jagan1961 jagan1961 Apr 13, 2015 12:29 PM Flag

    14 MLN shares shorted already. For the past 3/4 days if you look at the trading pattern there are more shorted shares. Even today it is overwhelming short position, how long they can generate this many phantom shares.

    They received 1 mg approval long ago, only 2 mg/4 mg multi dosage trial was on Hold. Today they can start multi-dosing trials 2 -4 mg.

    Everything is cleared for ARC 520 trials, incremental KD and functional cure with Multi-dosing trial is the Goal here.

    GLTA LONGS!

    Sentiment: Strong Buy

  • jagan1961 jagan1961 Apr 13, 2015 12:07 PM Flag

    In connection with an IND filed in December 2014, Arrowhead proposed a parallel design multiple-dose Phase 2b study testing doses of 2 mg/kg and 4 mg/kg simultaneously. In January 2015, the FDA notified the Company that a partial clinical hold had been placed on the program. In order to proceed with the proposed parallel design study, the FDA requested that the Company provide additional information including data from the single-dose Phase 2a study in patients who receive 1-4 mg/kg ARC-520, data from an ongoing multiple-dose non-clinical study, and data from Heparc-2004 which is now cleared to begin.

    I think they are starting with 1 mg/kg however they are allowed to go for 2 & 4 mg /kg now.

    GLTA LONGS!

    Sentiment: Strong Buy

  • It is worth a huge money when both ARC 520 and ARC AAT comes out. With the NVS portfolio acquisition you have 3 immediate Drug candidates in the Pipeline and another 30 Potential candidates.

    That is huge folks!

    GLTA LONGS!

    Sentiment: Strong Buy

AFFY
0.12+0.0100(+9.09%)Apr 24 11:22 AMEDT